A Phase 2 interventional study of 0.5 ml dose of 1.1 mcg VAX-24 and 0.5 ml dose of PCV20 in Pneumococcal Vaccines, sponsored by Vaxcyte, Inc.. Completed at 32 sites in United States. Open to participants aged 42 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by Vaxcyte, Inc. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 344 studies in Pneumonia with a site in United States — 40 open to participants now, 51 under way, 6 of them phase 3. Pneumonia · United States.
Among the 344 studies in Pneumonia with a site in United States, this one is the 35th largest by enrollment of the 263 interventional ones that give a count, is one of 15 that started in 2023, is one of 64 in phase 2, and was the 298th registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →40 of the 344 studies in Pneumonia with a site in United States are open now. Recruiting first, the newest first:
Seattle Institute for Biomedical and Clinical Research · Sites in United States
Ages 18+
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
MiNK Therapeutics · Sites in United States, Ukraine
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Quantec Ltd · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 42 Days to 89 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
344 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 81 · Phase 3 55 · Phase 4 32
First in 1994; this study’s year is marked. 15 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 802 is above the median of 128 across 978 interventional studies indexed under Pneumonia.
Median enrollment 91 across the 263 interventional studies, 325 across the 78 observational. Of the 259 that completed or were terminated, 101 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
118 of 344 have an industry lead sponsor. The 10 most frequent:
Vaxcyte, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
Vaxcyte, Inc. has 5 studies filed under Pneumonia — fewer than ten, so there is no comparison to draw.
20 of the studies in Pneumonia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
Add all 20 to your calendar (.ics) → With an account.
Among the 344 studies in Pneumonia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
Biological: 0.5 ml dose of 1.1 mcg VAX-24
Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
Biological: 0.5 ml dose of 2.2 mcg VAX-24
Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.
Biological: 0.5 ml dose of 2.2/4.4 mcg VAX-24
Participants will receive 4 doses of PCV20 administered as an intramuscular injection of the standard dose at 2, 4, 6, and 12-15 months of age.
Biological: 0.5 ml dose of PCV20
24 valent pneumococcal conjugate vaccine
20 valent pneumococcal conjugate vaccine
24 valent pneumococcal conjugate vaccine
24 valent pneumococcal conjugate vaccine
Percentage of participants with any solicited local injection site Adverse Events (AE) within 7 days after each vaccination
Solicited local reactions include erythema, edema, and tenderness at the injection site
Time frame: 7 days after each vaccination
Percentage of participants with any solicited systemic AE within 7 days after each vaccination
Solicited systemic reactions include fever, irritability, decreased appetite, decreased sleep, and increased sleep
Time frame: 7 days after each vaccination
Percentage of participants with any related Serious Adverse Events (SAE) within 6 months after last vaccination
Percentage of participants with related SAE
Time frame: 6 months after last vaccination
Percentage of subjects with any unsolicited AE within 1 month after each vaccination
Percentage of subjects with any unsolicited AE
Time frame: 1 month after each vaccination
Percentage of subjects with any unsolicited AE from Dose 1 through 1 month post-Dose 3
Percentage of subjects with any unsolicited AE between first and 3rd vaccination in the primary series
Time frame: First vaccination (Dose 1) through 1 month after third vaccination (Dose 3)
Percentage of subjects with any AE resulting in discontinuation of study within 6 months after last vaccination
Percentage of subjects with any AE resulting in discontinuation of study
Time frame: 6 months after last vaccination
Percentage of subjects with any new onset of chronic illness (NOCI) within 6 months after last vaccination
Percentage of subjects with any NOCI
Time frame: 6 months after last vaccination
Percentage of subjects with any medically attended adverse events (MAAE) within 6 months after last vaccination
Percentage of subjects with any MAAE
Time frame: 6 months after last vaccination
Percentage of subjects with any SAE within 6 months after last vaccination
Percentage of subjects with any SAE
Time frame: 6 months after last vaccination
Percentage of subjects achieving an anti-pneumococcal Immunoglobulin G (IgG) antibody concentration ≥0.35 mcg/mL 1 month after Dose 3
Percentage of subjects achieving an anti-pneumococcal IgG antibody concentration ≥0.35 mcg/mL
Time frame: 1 month after Dose 3
Percentage of subjects achieving an anti-pneumococcal IgG antibody concentration ≥0.35 mcg/mL 1 month after Dose 4
Percentage of subjects achieving an anti-pneumococcal IgG antibody concentration ≥0.35 mcg/mL
Time frame: 1 month after Dose 4
IgG antibody Geometric Mean Concentration (GMC) 1 month after Dose 3
Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24
Time frame: 1 month after Dose 3
IgG antibody GMC 1 month after Dose 4
Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24
Time frame: 1 month after Dose 4
Opsonophagocytic activity (OPA) Geometric Mean Titer (GMT) 1 month after Dose 3
Antibody geometric mean titers s as measured by OPA for the 24 pneumococcal serotypes in VAX-24
Time frame: 1 month after Dose 3
OPA GMT 1 month after Dose 4
Antibody geometric mean titers s as measured by OPA for the 24 pneumococcal serotypes in VAX-24
Time frame: 1 month after Dose 4
IgG Geometric Mean Fold Ratio (GMFR) before Dose 4 to 1 month after Dose 4
Antibody geometric mean fold ratio as measured by IgG for the 24 pneumococcal serotypes in VAX-24
Time frame: Pre-Dose 4 to 1 month after Dose 4
OPA GMFR before Dose 4 to 1 month after Dose 4
Antibody geometric mean fold rise as measured by OPA for the 24 pneumococcal serotypes in VAX-24
Time frame: Pre-Dose 4 to 1 month after Dose 4
Percentage of subjects achieving at least a 4-fold increase in IgG from pre-Dose 4 to 1 month post Dose 4
Geometric mean concentration with a at least a 4-fold increase in IgG antibodies for the 24 pneumococcal serotypes in VAX-24
Time frame: Pre-Dose 4 to 1 month after Dose 4
Percentage of subjects achieving at least a 4-fold increase in OPA titers from pre-Dose 4 to 1 month post Dose 4
Geometric mean titer with a at least a 4-fold increase in OPA titers for the 24 pneumococcal serotypes in VAX-24
Time frame: Pre-Dose 4 to 1 month after Dose 4
Plan to share: Yes — Vaxcyte is committed to providing access to anonymized data from the company's clinical trials for the purpose of legitimate scientific research. Requests for data may be addressed to datasharing@vaxcyte.com. Requests must be accompanied by a detailed analysis plan and will be reviewed for scientific validity. Data will be made available after initial product approval. Sharing of data may require execution of a data-sharing agreement.
Supporting information: Study protocol
Time frame: Individual participant data will be shared after deidentification and made available starting 6 months after initial product approval.
Access criteria: Criteria will depend on the specific proposal received and may include qualification of the scientific researchers, potential contribution to the research field, scientific rigor of statistical and analytical methods, and other criteria appropriate for the proposal.
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Aug 2025, 28 months.
Of 65 phase 2 interventional studies under Pneumonia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 28 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vaxcyte, Inc.